

Maria Martinez-Lage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5200496/publications.pdf>

Version: 2024-02-01

89
papers

9,704
citations

81900

39
h-index

74163

75
g-index

90
all docs

90
docs citations

90
times ranked

15407
citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent Acromegaly in a Patient With a CHEK2 Mutation. <i>AACE Clinical Case Reports</i> , 2022, 8, 85-88.	1.1	1
2	Reimagining the Clinical Competency Committee to Enhance Education and Prepare for Competency-Based Time-Variable Advancement. <i>Journal of General Internal Medicine</i> , 2022, 37, 2280-2290.	2.6	14
3	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	3.4	18
4	Unilateral Relapsing Primary Angiitis of the CNS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	9
5	Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations. <i>Neurologia Medico-Chirurgica</i> , 2021, 61, 385-391.	2.2	4
6	Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy. <i>European Journal of Cancer</i> , 2021, 144, 178-181.	2.8	5
7	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , 2021, 138, 382-386.	1.4	13
8	Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion. <i>Oncologist</i> , 2021, 26, 919-924.	3.7	6
9	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
10	Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	79
11	A Simplified Brain Blocking Protocol Optimized for the Diagnosis of Neurodegenerative Disease Saves Time and Money While Preserving Anatomic Relationships. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 960-968.	2.5	2
12	Defining Treatment-Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment-Induced Necrosis. <i>Oncologist</i> , 2020, 25, e1221-e1232.	3.7	23
13	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	21.4	177
14	Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. <i>Cancer</i> , 2020, 126, 2625-2636.	4.1	60
15	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	28.9	1,408
16	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. <i>Blood</i> , 2019, 134, 860-866.	1.4	178
17	Case 31-2019: A 45-Year-Old Woman with Headache and Somnolence. <i>New England Journal of Medicine</i> , 2019, 381, 1459-1470.	27.0	5
18	Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. <i>Neuro-Oncology</i> , 2019, 21, 1401-1411.	1.2	70

#	ARTICLE	IF	CITATIONS
19	Transcriptome signatures associated with meningioma progression. <i>Acta Neuropathologica Communications</i> , 2019, 7, 67.	5.2	36
20	Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. <i>Neuro-Oncology</i> , 2019, 21, 1118-1130.	1.2	37
21	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <i>PIK3CA</i> -Mutant Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3374-3383.	7.0	57
22	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , 2019, 3, 375-383.	5.2	77
23	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111.	1.2	1
24	Immune landscapes associated with different glioblastoma molecular subtypes. <i>Acta Neuropathologica Communications</i> , 2019, 7, 203.	5.2	112
25	Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2019, 142, 69-77.	2.9	39
26	A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. <i>Neurosurgery</i> , 2019, 85, 204-210.	1.1	28
27	Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging. <i>Journal of Neurosurgery</i> , 2018, 129, 390-403.	1.6	46
28	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	12.6	461
29	Thyroidosis Mistaken for Thyroid Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 540.	2.2	0
30	Case 5-2018: A 63-Year-Old Man with Confusion after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2018, 378, 659-669.	27.0	7
31	Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy. <i>Annals of Neurology</i> , 2018, 83, 311-327.	5.3	59
32	<i>In vivo</i> evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature. <i>Neuro-Oncology</i> , 2018, 20, 1068-1079.	1.2	90
33	Practical Implications of the Updated WHO Classification of Brain Tumors. <i>Seminars in Neurology</i> , 2018, 38, 011-018.	1.4	4
34	Near-infrared fluorescent image-guided surgery for intracranial meningioma. <i>Journal of Neurosurgery</i> , 2018, 128, 380-390.	1.6	62
35	NIMG-70. QUANTITATIVE IMAGE ANALYSIS AND MACHINE LEARNING TECHNIQUES FOR DISTINGUISHING TRUE PROGRESSION FROM PSEUDOPROGRESSION IN PATIENTS WITH GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi191-vi192.	1.2	7
36	NCMP-22. TREATMENT-RELATED ADVERSE EFFECTS IN PATIENTS WITH MALIGNANT GLIOMA: ESTABLISHMENT OF KEY FEATURES FOR PSEUDOPROGRESSION AND TREATMENT-INDUCED NECROSIS.. <i>Neuro-Oncology</i> , 2018, 20, vi198-vi198.	1.2	1

#	ARTICLE	IF	CITATIONS
37	GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi106-vi107.	1.2	0
38	MNGI-37. DMD GENOMIC DELETIONS CHARACTERIZE A SUBSET OF PROGRESSIVE/HIGHER-GRADE MENINGIOMAS WITH POOR OUTCOME. <i>Neuro-Oncology</i> , 2018, 20, vi157-vi157.	1.2	0
39	NIMG-64. A CLINICAL RULE FOR PREOPERATIVE PREDICTION OF BRAF MUTATION STATUS IN CRANIOPHARYNGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi190-vi190.	1.2	0
40	Neuropathology Education Using Social Media. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 454-460.	1.7	13
41	The role of proton beam therapy in central neurocytoma: A single-institution experience. <i>Practical Radiation Oncology</i> , 2018, 8, e305-e311.	2.1	1
42	Case 5-2018: A Man with Confusion after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2018, 378, 2544-2545.	27.0	0
43	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. <i>Acta Neuropathologica</i> , 2018, 136, 779-792.	7.7	66
44	<i>In Vivo</i> Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The <i>T</i> -Index. <i>Clinical Cancer Research</i> , 2017, 23, 4724-4734.	7.0	79
45	19-Year-Old Male with Headaches and a Possible Seizure. <i>Brain Pathology</i> , 2017, 27, 557-558.	4.1	2
46	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	1,116
47	Primary diffuse large B-cell lymphoma of the CNS: a rare case of spontaneous remission. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 69-73.	1.6	3
48	TMOD-11. A NOVEL ANIMAL MODEL OF MEDULLOBLASTOMA METASTASIS. <i>Neuro-Oncology</i> , 2017, 19, iv50-iv50.	1.2	0
49	Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomas. <i>Oncotarget</i> , 2017, 8, 109228-109237.	1.8	89
50	Near Infrared Folate-Targeted, Intraoperative Visualization of Pituitary Adenoma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.8	0
51	Intraoperative Near-Infrared Optical Imaging Can Localize Gadolinium-Enhancing Gliomas During Surgery. <i>Neurosurgery</i> , 2016, 79, 856-871.	1.1	116
52	Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma. <i>Neurosurgery</i> , 2016, 78, 572-580.	1.1	116
53	Population-based MRI atlases of spatial distribution are specific to patient and tumor characteristics in glioblastoma. <i>NeuroImage: Clinical</i> , 2016, 12, 34-40.	2.7	49
54	Prevalence of clinically silent corticotroph macroadenomas. <i>Clinical Endocrinology</i> , 2016, 85, 874-880.	2.4	16

#	ARTICLE	IF	CITATIONS
55	Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2016, 127, 391-400.	2.9	36
56	Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI. <i>American Journal of Neuroradiology</i> , 2016, 37, 28-36.	2.4	116
57	Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. <i>Neuro-Oncology</i> , 2016, 18, 417-425.	1.2	243
58	Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. , 2016, , .		3
59	Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2067-2067.	1.6	17
60	Neurodegenerative Disorders. , 2016, , 261-276.		0
61	Synovial-type giant cell tumors of the axial spine. <i>Journal of Neurosurgical Sciences</i> , 2016, 61, 106-109.	0.6	0
62	Lateral Transorbital Endoscopic Access to the Hippocampus, Amygdala, and Entorhinal Cortex: Initial Clinical Experience. <i>Orl</i> , 2015, 77, 321-332.	1.1	32
63	Management of an expansile orbital mass: Plexiform neurofibroma decompression by orbitozygomatic approach. <i>Laryngoscope</i> , 2015, 125, 2457-2460.	2.0	3
64	Factors Associated with Increased Survival after Surgical Resection of Glioblastoma in Octogenarians. <i>PLoS ONE</i> , 2015, 10, e0127202.	2.5	20
65	Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma. <i>Molecular Cancer Research</i> , 2015, 13, 1227-1237.	3.4	29
66	Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. <i>Translational Oncology</i> , 2014, 7, 752-758.	3.7	49
67	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. <i>Nature Genetics</i> , 2014, 46, 161-165.	21.4	408
68	Abstract 3428: Validation and utilization of next generation sequencing in the clinical assessment of gliomas. , 2014, , .		0
69	Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. <i>Acta Neuropathologica Communications</i> , 2013, 1, 36.	5.2	32
70	<sc><i>PDGFRA</i></sc> Amplification is Common in Pediatric and Adult Highâ€Grade Astrocytomas and Identifies a Poor Prognostic Group in <sc>IDH</sc> 1 Mutant Glioblastoma. <i>Brain Pathology</i> , 2013, 23, 565-573.	4.1	83
71	Mega-epsilon waves on 12-lead ECGâ€just another case of arrhythmogenic right ventricular dysplasia/cardiomyopathy?. <i>Journal of Electrocardiology</i> , 2013, 46, 524-527.	0.9	12
72	The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. <i>Modern Pathology</i> , 2013, 26, 1425-1432.	5.5	98

#	ARTICLE	IF	CITATIONS
73	Dry Beriberi and Wernicke's encephalopathy following gastric lap band surgery. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1050-1052.	1.5	22
74	TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation. <i>Acta Neuropathologica</i> , 2012, 124, 285-291.	7.7	24
75	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. <i>Neuron</i> , 2011, 69, 397.	8.1	7
76	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. <i>Archives of Neurology</i> , 2011, 68, 488.	4.5	108
77	Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. <i>Neurology</i> , 2011, 77, 589-593.	1.1	299
78	Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2010, 119, 111-122.	7.7	64
79	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010, 42, 234-239.	21.4	479
80	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. <i>Neuron</i> , 2010, 68, 857-864.	8.1	1,100
81	Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. <i>Journal of Neurology</i> , 2009, 256, 1205-1214.	3.6	167
82	Amyotrophic Lateral Sclerosis-Plus Syndrome With TAR DNA-Binding Protein-43 Pathology. <i>Archives of Neurology</i> , 2009, 66, 121-4.	4.5	52
83	Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies. <i>Archives of Neurology</i> , 2009, 66, 180-9.	4.5	232
84	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. <i>Lancet Neurology</i> , The, 2008, 7, 409-416.	10.2	636
85	Evidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 636-41.	4.5	251
86	Clinical and Pathological Heterogeneity of Neuronal Intermediate Filament Inclusion Disease. <i>Archives of Neurology</i> , 2008, 65, 272-5.	4.5	27
87	A novel antiganglioside specificity against terminal NeuNAc(alfa 2-3)Gal in acute bulbar palsy. <i>Journal of Neuroimmunology</i> , 2006, 176, 219-222.	2.3	5
88	Pretreatment Hemostatic Markers of Symptomatic Intracerebral Hemorrhage in Patients Treated With Tissue Plasminogen Activator. <i>Stroke</i> , 2006, 37, 996-999.	2.0	54
89	Does Thrombolysis Benefit Patients with Lacunar Syndrome?. <i>European Neurology</i> , 2006, 55, 70-73.	1.4	47